Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
COVID-19
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Shionogi's antiviral comes up short in global COVID-19 trial
May 13, 2024 10:48am
AGC plots around 100 layoffs amid tough business environment
May 10, 2024 11:40am
Sanofi pays $1.2B to partner with Novavax on COVID-19 vaccine
May 10, 2024 10:53am
Europe suspends AZ's marketing authorization for COVID vaccine
May 8, 2024 11:33am
BioNTech looks to 2026 for commercial debut in oncology
May 6, 2024 10:44am
More News
Moderna plots launch of its next potential mRNA vaccine approval
May 2, 2024 11:08am
GSK launches mRNA patent infringement case against Pfizer
Apr 26, 2024 10:04am
Pfizer focuses on long COVID in latest 'Dear Scientist' video
Apr 17, 2024 1:10pm
Judge pauses Moderna's infringement case against rival Pfizer
Apr 15, 2024 4:47pm
See more stories